The trial may begin from Wednesday, said a top official of the institute, one of the 17 sites selected for the phase 2 human trials in the country by Serum Institute of India (SII).
Doses of the potential coronavirus vaccine developed by researchers at Oxford University arrived at the Bharti Vidyapeeth’s Medical College here for phase-2 human trials on Tuesday, an official said. The trial may begin from Wednesday, said a top official of the institute, one of the 17 sites selected for the phase 2 human trials in the country by Serum Institute of India (SII).
“To start with we have identified five volunteers who will undergo COVID-19 and antibodies test. Those whosereports are negative will be shortlisted for vaccination on Wednesday,” said Dr Sanjay Lalwani, Medical Director, Bharti Vidyapeeth’s Medical College and Hospital and Research Centre. He said the hospital has been given a target of enlisting 300 to 350 volunteers. Those chosen for receiving a dose of vaccine will be in the age group of 18 to 99 years, he told PTI. Dr Jeetendra Oswal, deputy medical director of the hospital, said after they are administered the vaccine, the volunteers will be monitored as per the standard trial protocol.
- Coronavirus India updates: Active Covid-19 cases shrink to 4.6% of total positive cases; cumulative positivity rate 6.69%
- Supreme Court says will clarify position on homeopathic preventive treatment for COVID, reserves verdict
- Coronavirus in Delhi: Positivity rate should decelerate in next two weeks, says Health Minister Satyendar Jain
The other hospitals where trials are to be conducted include B J Medical College Hospital in Pune, AIIMS Delhi, Rajendra MemorialResearch Institute of Medical Sciences in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh,Nehru Hospital in Gorakhpur and Andhra Medical College in Visakhapatnam. SII, the world’s largest vaccine maker, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute of Oxford University in collaboration with British-Swedish pharma company AstraZeneca.